Low grade glioma with BRAF V600E mutation

Low-grade glioma with a BRAF V600E mutation is a molecularly defined subset of slow-growing, World Health Organization grade 1 or 2 neuroepithelial central nervous system neoplasms, most frequently encountered in pediatric and young adult populations Histologically encompassing entities such as gangliogliomas, pleomorphic xanthoastrocytomas, and certain pilocytic astrocytomas, these tumors develop primarily in the brain and spinal cord

Low-grade glioma with a BRAF V600E mutation is a molecularly defined subset of slow-growing, World Health Organization grade 1 or 2 neuroepithelial central nervous system neoplasms, most frequently encountered in pediatric and young adult populations Histologically encompassing entities such as gangliogliomas, pleomorphic xanthoastrocytomas, and certain pilocytic astrocytomas, these tumors develop primarily in the brain and spinal cord Relative to wild-type or fusion-driven counterparts, low-gra...

Pathophysiologically, the somatic *BRAF* V600E missense variant constitutively activates the intracellular MAPK/ERK signaling cascade, driving sustained oncogenic cell proliferation and survival

Pathophysiologically, the somatic *BRAF* V600E missense variant constitutively activates the intracellular MAPK/ERK signaling cascade, driving sustained oncogenic cell proliferation and survival

Relative to wild-type or fusion-driven counterparts, low-grade gliomas harboring this biomarker often exhibit a higher propensity for disease progression and a comparatively less durable response to standard cytotoxic chemotherapy

Relative to wild-type or fusion-driven counterparts, low-grade gliomas harboring this biomarker often exhibit a higher propensity for disease progression and a comparatively less durable response to standard cytotoxic chemotherapy